Tuhura Biosciences, Inc.
- Country
- 🇺🇸United States
- Ownership
- Subsidiary
- Established
- 1995-01-01
- Employees
- 11
- Market Cap
- -
- Website
- http://tuhurabio.com
Clinical Trials
6
Trial Phases
3 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (5 trials with phase data)• Click on a phase to view related trials
Placebo-Controlled Trial of IFx-Hu2.0 Followed By Pembrolizumab In Checkpoint Inhibitor Naïve Participants With Advanced Or Metastatic Merkel Cell Carcinoma
- Conditions
- Advanced Or Metastatic Merkel Cell Carcinoma
- Interventions
- First Posted Date
- 2025-04-27
- Last Posted Date
- 2025-10-14
- Lead Sponsor
- TuHURA Biosciences, Inc.
- Target Recruit Count
- 118
- Registration Number
- NCT06947928
- Locations
- 🇺🇸
USC Norris Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸Stanford Health Care - Skin Cancer Program, Palo Alto, California, United States
🇺🇸University of California San Francisco - Helen Diller Family Comprehensive Cancer Center, San Francisco, California, United States
IFx-Hu2.0 As An Adjunctive Therapy To Pembrolizumab In Advanced Or Metastatic Merkel Cell Carcinoma (MCC)
- Conditions
- Advanced Or Metastatic Merkel Cell Carcinoma
- Interventions
- First Posted Date
- 2025-04-23
- Last Posted Date
- 2025-10-15
- Lead Sponsor
- TuHURA Biosciences, Inc.
- Target Recruit Count
- 9
- Registration Number
- NCT06940440
- Locations
- 🇺🇸
H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
🇺🇸University of Wisconsin Carbone Cancer Center, Madison, Wisconsin, United States
IFx-Hu2.0 for the Treatment of Patients With Skin Cancer
- Conditions
- Basal Cell CarcinomaCutaneous Squamous Cell Carcinoma
- First Posted Date
- 2021-06-14
- Last Posted Date
- 2024-08-02
- Lead Sponsor
- TuHURA Biosciences, Inc.
- Target Recruit Count
- 5
- Registration Number
- NCT04925713
- Locations
- 🇺🇸
Moore Clinical Research, Brandon, Florida, United States
IFx-Hu2.0 Expanded Access Program
- Conditions
- Cutaneous Melanoma, Stage IIICutaneous Melanoma, Stage IVMerkel Cell CarcinomaCutaneous Squamous Cell Carcinoma
- First Posted Date
- 2021-04-21
- Last Posted Date
- 2024-08-12
- Lead Sponsor
- TuHURA Biosciences, Inc.
- Registration Number
- NCT04853602
Immunotherapy With IFx-Hu2.0 Vaccine for Advanced Non-melanoma Skin Cancers
- Conditions
- Non-Melanoma Skin CancersMerkel Cell CarcinomaCutaneous Squamous Cell Carcinoma
- Interventions
- First Posted Date
- 2019-11-12
- Last Posted Date
- 2024-08-05
- Lead Sponsor
- TuHURA Biosciences, Inc.
- Target Recruit Count
- 23
- Registration Number
- NCT04160065
- Locations
- 🇺🇸
USC Norris Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
- Prev
- 1
- 2
- Next